Table 4.
Hazard ratio of CAZ/AVI-based therapeutic regimens and 30-day mortality according to the subgroup analysis
| Subgroupa | n | HR | 95% CI | P value |
|---|---|---|---|---|
| CAZ/AVI + carbapenemb | 17 | 0.585 | 0.325–1.053 | 0.074 |
| CAZ/AVI + tigecycline | 11 | 0.267 | 0.077–0.921 | 0.037 |
| CAZ/AVI + amikacin | 11 | 0.105 | 0.014–0.766 | 0.026 |
| CAZ/AVI + fosfomycin | 7 | 0.299 | 0.077–1.160 | 0.081 |
| CAZ/AVI monotherapy | 33 | 0.591 | 0.332–1.054 | 0.075 |
HR hazard ratio, CI confidence interval
aAdjusted for age (> 65 years), CRRT, sepsis, organ transplantation, sex (female), antimicrobial treatment duration (> 7 days)
bFourteen patients received meropenem and three patients received imipenem